Correlation Between Valens and Raphael Pharmaceutical

Can any of the company-specific risk be diversified away by investing in both Valens and Raphael Pharmaceutical at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Valens and Raphael Pharmaceutical into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Valens and Raphael Pharmaceutical, you can compare the effects of market volatilities on Valens and Raphael Pharmaceutical and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Valens with a short position of Raphael Pharmaceutical. Check out your portfolio center. Please also check ongoing floating volatility patterns of Valens and Raphael Pharmaceutical.

Diversification Opportunities for Valens and Raphael Pharmaceutical

0.42

Correlation Coefficient

Valens  Raphael Pharmaceutical

Very weak diversification

The 3 months correlation between Valens and Raphael is 0.42. Overlapping area represents the amount of risk that can be diversified away by holding Valens and Raphael Pharmaceutical in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Raphael Pharmaceutical and Valens is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Valens are associated (or correlated) with Raphael Pharmaceutical. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Raphael Pharmaceutical has no effect on the direction of Valens i.e., Valens and Raphael Pharmaceutical go up and down completely randomly.

Pair Corralation between Valens and Raphael Pharmaceutical

Considering the 90-day investment horizon Valens is expected to generate 0.42 times more return on investment than Raphael Pharmaceutical. However, Valens is 2.37 times less risky than Raphael Pharmaceutical. It trades about 0.03 of its potential returns per unit of risk. Raphael Pharmaceutical is currently generating about -0.13 per unit of risk. If you would invest  218.00  in Valens on September 14, 2024 and sell it today you would earn a total of  5.00  from holding Valens or generate 2.29% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	98.44%
Values	Daily Returns

Valens  vs.  Raphael Pharmaceutical

Valens

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Valens are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating essential indicators, Valens may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Raphael Pharmaceutical

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Raphael Pharmaceutical has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in January 2025. The recent confusion may also be a sign of long-lasting up-swing for the firm traders.

Pair Trading with Valens and Raphael Pharmaceutical

The main advantage of trading using opposite Valens and Raphael Pharmaceutical positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Valens position performs unexpectedly, Raphael Pharmaceutical can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Raphael Pharmaceutical will offset losses from the drop in Raphael Pharmaceutical's long position.

The idea behind Valens and Raphael Pharmaceutical pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.